Invesco Ltd. Glycomimetics Inc Transaction History

Invesco Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$2.89 - $4.22 $121,879 - $177,970	-42,173 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.69 - $4.24 $10,730 - $16,913	3,989 Added 10.45%	42,173 $159,000
Q3 2020 Nov 16, 2020	SELL	$3.07 - $5.0 $3,343 - $5,445	-1,089 Reduced 2.77%	38,184 $117,000
Q2 2020 Aug 14, 2020	SELL	$2.06 - $3.76 $4.84 Million - $8.83 Million	-2,349,033 Reduced 98.36%	39,273 $148,000
Q1 2020 May 15, 2020	SELL	$1.83 - $5.41 $4.36 Million - $12.9 Million	-2,384,418 Reduced 49.96%	2,388,306 $5.44 Million
Q4 2019 Feb 14, 2020	BUY	$4.03 - $6.5 $44,039 - $71,032	10,928 Added 0.23%	4,772,724 $25.2 Million
Q3 2019 Nov 14, 2019	SELL	$2.8 - $12.85 $13,162 - $60,407	-4,701 Reduced 0.1%	4,761,796 $20.5 Million
Q2 2019 Aug 14, 2019	BUY	$10.6 - $13.12 $50.5 Million - $62.5 Million	4,766,497 New	4,766,497 $56.8 Million

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $20.4M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.